@article{b055a588511846adbf2575aae7af7c84,
title = "Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis",
abstract = "Stem cell transplantation was one of the first proven effective regimens for the management of immunoglobulin light-chain amyloidosis. Criteria for patient selection and the mobilization regimen become important features in ensuring a safe outcome. The technique of stem cell transplantation has evolved considerably in parallel with the development of new chemotherapeutic agents for the management of amyloidosis. Optimal outcomes require both the use of effective novel agent induction and appropriate application of high-dose chemotherapy with subsequent stem cell reconstitution.",
keywords = "High-dose chemotherapy, Melphalan, Mobilization, Transplantation",
author = "Gertz, {Morie A.} and Stefan Schonland",
note = "Funding Information: S. Schonland research support from Janssen and Sanofi, serves on the advisory boards for Janssen and Prothena and has received honoraria from Janssen, Takeda, and Prothena; M.A. Gertz personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Celgene, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, personal fees from Research to Practice, speaker fees from Teva, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health. Funding Information: S. Schonland research support from Janssen and Sanofi , serves on the advisory boards for Janssen and Prothena and has received honoraria from Janssen, Takeda, and Prothena; M.A. Gertz personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Celgene, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, personal fees from Research to Practice, speaker fees from Teva, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = dec,
doi = "10.1016/j.hoc.2020.07.007",
language = "English (US)",
volume = "34",
pages = "1133--1144",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",
}